Receptor Grade IGF-1 LR3 – 1MG

Scientific Overview of Receptor Grade IGF-1 LR3

Receptor Grade IGF-1 LR3, also known as insulin-like growth factor-1 long arginine 3, is a modified form of insulin-like growth factor-1 (IGF-1) designed for use in experimental research. IGF-1 and its analogs have been central to studies examining cellular proliferation, communication, and signaling mechanisms. One of the distinctive features of IGF-1 LR3 is its reduced affinity for insulin-like growth factor binding proteins (IGFBPs), a family of proteins that regulate the distribution and accessibility of IGFs within circulation. By binding less strongly to these proteins, IGF-1 LR3 may remain more available to interact with cellular receptors in experimental contexts.

Structural modifications to IGF-1 LR3—specifically the inclusion of additional amino acids at the N-terminus and a substitution at position three—have been associated with enhanced receptor affinity. This adaptation may influence its dynamics in cell culture models, offering researchers opportunities to explore pathways of growth and survival signaling. The designation “Receptor Grade” refers to the purity level of the preparation, which is generally higher than that of “Media Grade,” making it suitable for studies focused on receptor-specific interactions.

Receptor Grade IGF-1 LR3 Studies and Research Data

Investigations on Cellular Proliferation

Research suggests that IGF-1 LR3 may encourage cellular division and maturation across multiple tissue types, including those of muscle, bone, and liver. In laboratory models, IGF-1 LR3 has been observed to initiate stronger receptor activation than the parent molecule, potentially resulting in more robust cellular responses. Some studies in animal models under stress conditions indicated a reduction in markers of protein breakdown when exposed to IGF-1 LR3, suggesting a potential role in preserving structural proteins.

Receptor Grade IGF-1 LR3 Explorations into Myostatin Interaction

Myostatin, also referred to as growth differentiation factor 8, is recognized as a natural regulator of muscle growth. Experimental findings indicate that IGF-1 LR3 may counteract some of myostatin’s inhibitory actions on muscle cell proliferation. Investigations in preclinical models, including those involving muscle degeneration, suggest that IGF-1 derivatives may support the preservation of muscle cells and influence key regulatory proteins such as MyoD.

Considerations for Metabolic Pathways

In metabolic research, IGF-1 LR3 has been examined for its role in glucose handling and energy balance. Findings suggest that it may initiate signaling cascades involving PI3K and AMPK, pathways associated with nutrient regulation and energy use. Through these routes, IGF-1 LR3 may promote the movement of glucose transporters to the cell surface, facilitating uptake into experimental cell systems. Such activity has been associated with altered lipid and carbohydrate turnover, making IGF-1 LR3 a subject of interest in studies addressing cellular metabolism.

Receptor Grade IGF-1 LR3 Longevity-Related Research

Preclinical research has also explored IGF-1 LR3 in the context of tissue maintenance and survival. Observations in large animal models such as cattle and swine have suggested that IGF-1 LR3 exposure may be associated with sustained cellular turnover. In mouse studies, IGF-1 LR3 continues to be investigated for its potential role in processes linked to aging and degeneration, including those involving muscle, neurological function, and renal integrity.

Conclusion

Receptor Grade IGF-1 LR3 represents a structurally modified analog of IGF-1 with reduced affinity for binding proteins and increased receptor availability. Research has suggested roles for this compound in cellular proliferation, interactions with myostatin, metabolic signaling pathways, and tissue maintenance studies. While these findings highlight areas of scientific interest, outcomes remain subject to further experimental validation.

References

1. Li N, Yang Q, Walker RG, Thompson TB, Du M, Rodgers BD. Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis. Endocrinology. 2016;157(1):282-91.
2. AsghariHanjani N, Vafa M. The role of IGF-1 in obesity, cardiovascular disease, and cancer. Med J Islam Repub Iran. 2019;33:56.
3. Philippou A, Barton ER. Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res. 2014;24(5):157-63.
4. Bailes J, Soloviev M. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules. 2021;11(2):217.
5. Tomas FM, Knowles SE, Owens PC, Chandler CS, Francis GL, Read LC, Ballard FJ. Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. Biochem J. 1992;282:91-7.
6. Assefa B, Mahmoud AM, Pfeiffer AFH, Birkenfeld AL, Spranger J, Arafat AM. Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxid Med Cell Longev. 2017;2017:3035184.

Disclaimer:
The products mentioned are intended solely for laboratory research and in-vitro experimentation. They are not approved for human or animal use of any kind. All details provided are for educational purposes only. By purchasing from this site, you agree to comply with our Terms and Conditions.